Sep 12, 2017 · Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), the best known cases of Gram-positive resistance, are increasingly prevalent and may be associated with significantly worse clinical outcomes versus wild-type strains using current therapeutics.

May 30, 2023 · Gram-positive bacteria comprise cocci, bacilli, or branching filaments. Gram-positive cocci include Staphylococcus (catalase-positive), which grows clusters, and Streptococcus (catalase-negative), which grows in chains.

Jan 16, 2024 · The treatment for Gram-positive bacterial infections typically includes antibiotics. The type of antibiotic depends on the specific bacteria causing the infection. Common options for treating...

This review presents data on in vitro susceptibilities of aerobically growing Gram-positive rods and in vivo activities of antibiotics used against Gram-positive rods.

We reviewed nine antibiotics with predominant Gram-positive activity and focused on the treatment of IE and osteomyelitis (including osteosynthesis-associated infections). For some antibiotics such as ceftaroline, daptomycin, and linezolid, a …

Treatment of diseases caused by resistant gram-positive bacteria requires appropriate use of available antibiotics and stewardship to prolong their effectiveness. In addition, appropriate and aggressive infection control efforts are vital to help prevent the spread of resistant pathogens.

Sep 15, 2023 · From a clinical point of view, almost all of the new anti-Gram-positive antibiotics have been approved for ABSSSI, and 3 out of 7 of them have been approved for CABP (ceftaroline, ceftobiprole, omadacycline, and delafloxacin). Among them, ceftobiprole has also been approved for HAP.

Most infections due to Gram-positive organisms can be treated with quite a small number of antibiotics. Penicillin, cloxacillin, and erythromycin should be enough to cover 90 per cent of Gram-positive infections.

Apr 7, 2017 · This narrative review aims to provide a summary of existing evidence on efficacy, microbiological spectrum and safety of novel systemic antibiotics that have either recently been licensed or completed phase III trials, and possess activity predominantly against Gram …

Gram-positive bacteria have shown a propensity to develop resistance to all of the available antibiotics in use. Additionally, the superiority data for any one agent rather than another is lacking, with the possible exception of linezolid, rather than vancomycin, for the treatment of MRSA pneumonia.